| Main centres: | 1-3 business days |
| Regional areas: | 3-4 business days |
| Remote areas: | 3-5 business days |
Maximum success
Tirzepatide 15 mg is the highest studied weekly dose for chronic weight management. It works through two natural hormone pathways to reduce hunger, increase fullness, and support better blood sugar control.
Patients in clinical trials saw significant, sustained weight loss alongside improved cardiometabolic health.
Based on clinical trial data and regulatory approvals, the health benefits of Tirzepatide (brand names Mounjaro® and Zepbound®) extend beyond weight loss to include several specific, approved medical uses.
Here are the primary health benefits:
· Weight Management: The FDA has approved it for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition . In a Phase 3 trial, it led to an average weight loss of 20.2% (compared to 13.7% for Semaglutide) .
· Obstructive Sleep Apnea (OSA): It is the first medication specifically approved by the FDA to treat moderate-to-severe OSA in adults with obesity, significantly reducing the apnea-hypopnea index (AHI) .
· Glycemic Control (Type 2 Diabetes): For those with type 2 diabetes, it significantly reduces HbA1c levels (by over 2% in trials) by stimulating insulin release .
· Cardiovascular Risk Reduction: Real-world data suggests tirzepatide significantly lowers the risk of major adverse cardiovascular events (MACE), heart failure, stroke, and all-cause mortality in patients with type 2 diabetes .
· Metabolic Dysfunction-Associated Steatohepatitis (MASH): It has shown efficacy in improving markers of MASH (previously known as NASH), with a case report showing histological improvement, including reversal of cirrhosis in a patient unresponsive to other GLP-1 drugs .
Important Medical Considerations
Tirzepatide works by activating GIP and GLP-1 receptors to reduce appetite . Because it affects multiple systems, you should not use it if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. Common side effects include nausea, diarrhea, and vomiting .
Medical Disclaimer:
This information is for general educational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication; you should not obtain or use it without a prescription from a licensed healthcare provider. Always consult a qualified physician to discuss your full medical history, current medications, and potential risks (including but not limited to thyroid tumors, pancreatitis, gallbladder problems, and severe gastrointestinal issues). Never change your dosage or stop prescribed treatment without your doctors approval. Do not use Tirzepatide if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.
